Literature DB >> 6789937

Long survival in acute myelogenous leukaemia.

C B Freeman, R Harris, G M Taylor.   

Abstract

Entities:  

Mesh:

Year:  1981        PMID: 6789937      PMCID: PMC1506069          DOI: 10.1136/bmj.283.6284.139

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


× No keyword cloud information.
  6 in total

1.  Active immunotherapy for the treatment of acute myelogenous leukaemia: report of two controlled trials.

Authors:  J A Whittaker; R Bailey-Wood; S Hutchins
Journal:  Br J Haematol       Date:  1980-07       Impact factor: 6.998

2.  Influence of HLA, ABO, and Rh(D) on survival after remission in acute myelogenous leukaemia.

Authors:  R Harris; S R Zuhrie; G M Taylor; C B Freeman; J Wentzel; C Geary; J E MacIver
Journal:  Lancet       Date:  1977-09-24       Impact factor: 79.321

3.  Active immunotherapy used alone for maintenance of patients with acute myeloid leukaemia.

Authors:  C B Freeman; R Harris; C G Geary; M J Leyland; J E MaCiver; I W Delamore
Journal:  Br Med J       Date:  1973-12-08

4.  Correlation of clinical findings with quinacrine-banded chromosomes in 90 adults with acute nonlymphocytic leukemia: an eight-year study (1970-1977).

Authors:  H M Golomb; J W Vardiman; J D Rowley; J R Testa; U Mintz
Journal:  N Engl J Med       Date:  1978-09-21       Impact factor: 91.245

5.  HLA linked resistance factors and survival in acute myelogenous leukemia.

Authors:  R T Oliver; A Pillai; P T Klouda; S D Lawler
Journal:  Cancer       Date:  1977-06       Impact factor: 6.860

6.  Immunotherapy alone vs no maintenance treatment in acute myelogenous leukaemia.

Authors:  S R Zuhrie; R Harris; C B Freeman; J E MacIver; C G Geary; I W Delamore; J A Tooth
Journal:  Br J Cancer       Date:  1980-03       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.